2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus

Abstract

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease that represents a prodigious challenge of diagnosis and treatment. In 2019, under the leadership of the Chinese Rheumatology Association, a multidisciplinary guideline development group was established to develop an evidence-based diagnosis and treatment guideline for patients with SLE in PR China. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to evaluate the quality of evidence and the strength of recommendations. The guideline was reported following the Reporting Items for Practice Guidelines in Healthcare (RIGHT) checklist. In this guideline, we provided recommendations for SLE classification criteria, disease activity monitoring and assessment, medication administration and considerations for SLE patients with organs and systems involved, and management of special populations such as SLE patients in the setting of pregnancy. This guideline serves as an evidence-based tool for Chinese clinicians to diagnose and treat patients with SLE.

Sysmex UN2000 detection of protein/creatinine ratio and of renal tubular epithelial cells can be used for screening lupus nephritis

“…SLE group: (1) Patients who were with a final diagnosis of SLE made by the clinician in accordance with the 2012 systemic lupus erythematosus international lupus research clinical collaboration group (SLICC) or SLE classification standard formulated by EULAR / ACR in 2019[ 12 ]. (2) Patients were excluded when they were with diabetes, allergic purpura and other diseases that may cause acute and chronic kidney injury, or patients with kidney disease and other urinary system diseases.…”

Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus

“…The management of NPSLE can be challenging, because of the complexity of its pathogenesis, difficulty in its accurate diagnosis, and a lack of clinical trials in NPSLE. Current treatment options for NPSLE are usually derived from observational studies and refer to the experience of treatment of other SLE subtypes, such as lupus nephritis and similar neuropsychiatric disorders [ 8 , 75 ].…”

Progress of exosome research in systemic lupus erythematosus

“…Clinically, the conventional treatment for SLE is glucocorticoids, antimalarials, and immunosuppressive drugs. Combining these three types of drugs improves patient prognosis, but they exhibit poor targeting, are needed in high doses, and have long administration times and high recurrence rates [5] , [6] , [7] . Studies have shown that infection (33.2%), renal degeneration (18.7%), encephalopathy (13.8%), and cardiovascular disease (11.5%) are the main causes of death in SLE patients.…”